Class / Patent application number | Description | Number of patent applications / Date published |
424198100 | Hormone or other secreted growth regulatory factor, differentiation factor, intercellular mediator, neurotransmitter, or fragment thereof | 27 |
20080206277 | Isolated Nucleic Acid Molecule Encoding a Neurotrophic Growth Factor - There is disclosed an isolated nucleic acid molecule encoding a human neurotrophic growth factor designated enovin and having the amino acid sequence illustrated in FIG. | 08-28-2008 |
20080213301 | COMPOSITIONS AND METHODS FOR HEALTHY PREGNANCY - Compositions, kits and methods for the prevention of, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure during assisted reproduction are provided. The compositions, kits and methods provide an effective amount of granulocyte colony stimulating factor to prevent, for example, spontaneous abortion, preeclampsia, preterm labor or implantation failure of an embryo. | 09-04-2008 |
20080220013 | Diagnostic Method for Brain Damage-Related Disorders - A brain damage-related disorder is diagnosed in a subject by detecting at least one polypeptide, or a variant or mutant thereof, in a sample of body fluid taken from the subject, wherein the polypeptide is one for which the level is either increased or decreased in cerebrospinal fluid from deceased patients compared to cerebrospinal fluid from healthy donors. | 09-11-2008 |
20080286301 | Treatment of diabetes - Insulin-requiring diabetes in a mammal can be treated by a process comprising administering to the mammal in a suitable regimen an effective amount of insulin and an effective amount of a peptide comprising a peptide selected from the group consisting of
| 11-20-2008 |
20090110693 | MULTIMERIC COMPLEXES OF ANTIGENS AND AN ADJUVANT - The invention relates to a product which comprises a C4bp domain of a non-mammalian origin, particularly SEQ ID NO:1, SEQ ID NO:23 or SEQ ID NO:37, or a variant thereof, and an antigen. The product is desirably in the form of a fusion protein. The chicken C4bp domain of SEQ ID NO:1 and SEQ ID NO:23 is also described. Antigens include monomeric antigens such as malarial and influenza antigens. The C4bp domain provides for assembly of multimeric complexes of the antigen, or mixtures thereof. The complexes are useful as vaccines. | 04-30-2009 |
20100021496 | METHODS, KITS, AND ANTIBODIES FOR QUANTITATIVE DETERMINATION OF PARATHYROID HORMONE MOLECULES WITH INTACT C-TERMINUS - The present invention relates to novel methods and compositions useful for detecting whole parathyroid hormone at a physiological level and C-terminal parathyroid fragments in a mammalian sample. Such detections may be useful to different parathyroid diseases or disorders in a subject, such as chronic renal failure, hyperparathyroidism and related bone diseases, from normal or non-disease states. One detects whole or non-fragmented (1 to 84) parathyroid hormone in a biological sample and optionally one or more of a selection of C-terminal parathyroid hormone peptide fragments that may or may not function as a parathyroid hormone antagonists. By either comparing values or using independently the value of either the one or more of a selection of C-terminal parathyroid hormone peptide fragments, the whole parathyroid hormone, or the combination of these values, one is able to differentiate chronic renal failure, parathyroid and bone related disease states, as well as differentiate such states from normal states. | 01-28-2010 |
20100136046 | RECOMBINANT POLYPROTEIN VACCINES FOR THE TREATMENT AND DIAGNOSIS OF LEISHMANIASIS - Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise fusion polypeptides comprising multiple | 06-03-2010 |
20100143401 | VACCINE PREVENTING AND/OR TREATING AUTOIMMUNE DISEASES - The present invention discloses a vaccine preventing and/or treating autoimmune diseases. Its active component is: the mixture consisting of a protein antigen causing an autoimmune disease or the epitope polypeptides thereof, and the recombinant eukaryotic vector with the coding genes of an autoantigen or the epitope polypeptides thereof inserted into multiple cloning sites. The autoantigen is insulin, glutamic acid decarboxylase or heat shock protein, myelin oligodendrocyte glycoprotein, two myelin antigens, zona pellucida 3, myoglobulin, type II collagen, thyroglobulin, cell membrane surface antigen, type II colloid antigen, acetylcholine receptor, thyrocyte cell surface antigen, salivary gland duct antigen, thyroglobulin, superantigen, or interphotoreceptor retinoid binding protein. The vaccine can inhibit the proliferation of T cells of immune animals and humans, induce the occurrence of immune suppression, as well as prevent and/or treat autoimmune diseases effectively. | 06-10-2010 |
20100150957 | PEPTIDES FOR ACTIVE ANTI-CYTOKINE IMMUNIZATION - Peptide of a size comprised between 5 and 40 amino acids, originating from a cytokine, in which at least one of its amino acids comprises at least one of its atoms separated by a distance d of less than 5 angströms from an atom of the receptor corresponding to said cytokine, the spacing d being evaluated on the basis of structural data, derivatives, immunogenic compounds comprising them, use of a peptide or peptide derivative or immunogenic compound for the preparation of a curative or preventative medicament intended for the treatment or prevention of diseases linked to an excess or to the presence of cytokines or for the treatment of an auto-immune disease and pharmaceutical compositions which contain at least one abovementioned peptide or peptide derivative or immunogenic compound as active ingredient. | 06-17-2010 |
20110052625 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE - Pharmaceutical compositions and methods are provided for treating diabetes and/or restoring β-cell mass and function in a mammal in need thereof. Type 1 diabetes mellitus (T1DM) is an autoimmune disorder characterized by immune damage to pancreatic beta-cells. Lisofylline analogs (LSF analogs) are immunomodulators that reduce interlukin 12 signaling and reduce the onset of T1DM in non-obese diabetic (NOD) mice. A combination therapy with both LSF analog (pretreatment) and INGAP provides protection from autoimmune destruction. The concomitant or combination of an LSF analog and INGAP after pre-treatment with an LSF analog is an effective therapy for a disease or condition resulting from the loss of pancreatic islet cells or insulin production in a mammal. | 03-03-2011 |
20110064762 | PROTEIN A COMPOSITIONS AND METHODS OF USE - Methods and compositions for modulating an immune response in a subject are provided. Methods include administering to the subject a composition comprising an effective amount of a lymphocyte differentiation factor, e.g., protein A (PA), sufficient to modulate the immune response. Compositions include a lymphocyte differentiation factor, e.g., protein A (PA), in an amount less than 1 μg. | 03-17-2011 |
20110086061 | Cancer Detection Methods and Reagents - The present invention comprises methods and compositions for detecting cancer in an individual comprising autoantibodies to cancer-associated antigens. Specifically, the present invention comprises methods and compositions for detecting autoantibodies to cancer-associated antigen in a bodily fluid as well as use of said autoantibodies as a means to detect the presence of cancer-associated antigens. | 04-14-2011 |
20110274718 | System for Modulating Expression of Hypothalmic Brain-Derived Neurotrophic Factor (BDNF) - Methods for treating tumor associated diseases by administering a nucleic acid sequence encoding brain derived neurotrophic factor (BDNF) where the expression reduces the symptoms of the disease and compositions for mediation of enrichment-induced tumor resistance having brain derived neurotrophic factor (BDNF) are disclosed. | 11-10-2011 |
20110293654 | SUBSTITUTED CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS - Substituted fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a —CH(—R | 12-01-2011 |
20120014987 | DNA VACCINE FOR ALZHEIMER'S DISEASE - The present invention aims to provide a DNA vaccine for Alzheimer's disease. | 01-19-2012 |
20120171242 | Modified Antibody - Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules. | 07-05-2012 |
20130058970 | INDUCED TOLEROGENIC DENDRITIC CELLS TO REDUCE SYSTEMIC INFLAMMATORY CYTOKINES - Disclosed are induced tolerogenic dendritic cells (itDCs), as well as related compositions and methods, for reducing systemic inflammatory cytokines. | 03-07-2013 |
20130209505 | CRYSTALLINE FORM OF (2S,4R)-5-BIPHENYL-4-YL-2-HYDROXYMETHYL-2-METHYL-4-[(1H-[1,2,3]TRIAZOLE-4- -CARBONYL)-AMINO]-PENTANOIC ACID 5-METHYL-2-OXO-[1,3]DIOXOL-4-YLMETHYL ESTER - The invention provides a crystalline form of (2S,4R)-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-4-[(1H-[1,2,3]triazole-4-carbonyl)amino]pentanoic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester or its tautomer. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases. | 08-15-2013 |
20130259897 | CRYSTALLINE FORMS OF (R)-3-[N-(3'-CHLOROBIPHENYL-4-YLMETHYL)-N'-(3-HYDROXYISOXAZOLE-5-CARBONYL- )HYDRAZINO]-2-HYDROXYPROPIONIC ACID ISOPROPYL ESTER - The invention provides crystalline forms of (R)-3-[N-(3′-chlorobiphenyl-4-ylmethyl)-N′—(3-hydroxyisoxazole-5-carbonyl)hydrazino]-2-hydroxypropionic acid isopropyl ester. This invention also provides pharmaceutical compositions comprising the crystalline compound, processes and intermediates for preparing the crystalline compound, and methods of using the crystalline compound to treat diseases. | 10-03-2013 |
20130309267 | CANCER IMMUNOTHERAPY COMPOSITIONS AND METHODS OF USE - Cellular compositions and methods for inducing an immune response to tumor cells are described. The cellular compositions include a tumor antigen and cells that have been modified to express a cytokine and one or more of a tumor antigen, anti-CTLA4 antibody and an additional cytokine. The cellular compositions find utility in methods for treating cancer. | 11-21-2013 |
20140065184 | HLA-G Isoform for use in the Treatment of a Disease Associated with Bone Resorption - Novel use of HLA-G isoforms in the treatment or prevention of diseases in which bone resorption is observed. | 03-06-2014 |
20140294889 | USE OF THE PACAP AS A MOLECULAR ADJUVANT FOR VACCINES - The present invention relates to the use of the pituitary adenylate cyclase activating peptide (PACAP) as a molecular adjuvant for vaccines. Among other applications, these vaccines may be used in the protection against infectious agents such as viruses, bacteria and ectoparasites affecting mammals, birds and aquatic organisms. The PACAP, combined with a particular antigen, demonstrates its effectiveness as adjuvant increasing the host immune response against that antigen. This type of response can be observed when the vaccine compositions or combinations that include PACAP are administered orally, by injection, or by immersion baths, in case of aquatic organisms. | 10-02-2014 |
20150132340 | CATIONIC LIPID VACCINE COMPOSITIONS AND METHODS OF USE - The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one therapeutic factor. The disclosure also provides methods of reducing an immune suppressor cell population in a mammal, methods of augmenting an immune response in a mammal, and methods of treating a disease in a mammal utilizing the vaccine compositions. | 05-14-2015 |
20150297691 | USE OF ANTAGONISTS OF GHRELIN OR GHRELIN RECEPTOR TO PREVENT OR TREAT STRESS-SENSITIVE PSYCHIATRIC ILLNESS - The invention relates to methods of protecting against chronic stress in a subject and treating stress sensitive disorders in a subject by antagonizing ghrelin or ghrelin receptor. | 10-22-2015 |
20160058851 | USE OF ANTAGONISTS OF GHRELIN OR GHRELIN RECEPTOR TO PREVENT OR TREAT STRESS-SENSITIVE PSYCHIATRIC ILLNESS - The invention relates to methods of protecting against chronic stress in a subject and treating stress sensitive disorders in a subject by antagonizing ghrelin or ghrelin receptor. | 03-03-2016 |
20160074352 | NEPRILYSIN INHIBITORS - In one aspect, the invention relates to compounds having the formula: | 03-17-2016 |
20160175413 | METHOD AND COMPOSITION FOR TREATING SARCOPENIA | 06-23-2016 |